Jon D. Larson
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Previous Organizations / Institutes
The organizations / institutes from the scholar's other articles in the past ten years
Research Subjects
Jon D. Larson has a total of 100 co-authors. Here are the top co-authors by number of shared publications:
- Robert J. Wechsler-Reya
Cancer Genome and Epigenetics Program, National Cancer Institute-Designated Cancer Center, Sanford Burnham Prebys Medical Discovery Institute
19 shared publications - Adrian Contreras
Department of Urology, University of California, San Francisco, California
15 shared publications - Christin Schmidt
Helen Diller Family Comprehensive Cancer Center, University of California, San Francisco, California
15 shared publications - Davide Ruggero
Department of Urology, University of California, San Francisco, San Francisco, CA, USA; Helen Diller Family Comprehensive Cancer Center, University of California, San Francisco, San Francisco, CA, USA; Department of Cellular and Molecular Pharmacology, University of California, San Francisco, San Francisco, CA, USA
15 shared publications - Duygu Kuzuoglu-Ozturk
Department of Biochemistry, Max Planck Institute for Developmental Biology, Spemannstrasse 35, D-72076 Tübingen, Germany
15 shared publications - Hao Shao
Institute for Neurodegenerative Diseases, UCSF, San Francisco, California, USA
15 shared publications
Latest Publications
- Open Access
- 10 August 2026
- Published by Oxford University Press (OUP) in Neuro-Oncology
CD155 regulates tumor growth and susceptibility to T cell-mediated killing in diffuse midline glioma
Background: Diffuse midline glioma (DMG) is a devastating pediatric brain tumor with an unmet need for novel therapies. Immune-checkpoint inhibitors have failed to prolong survival of DMG patients. Methods: In this study, we screened for immune-checkpoint molecules in DMG, evaluated immunological responses to checkpoint targeting by coculture assays and depletion of immune cells in vivo, studied the effects of CD155 silencing by whole-transcriptome analyses and performed in vivo treatments with Thiostrepton (Thio). Results: In human and murine DMG cells, as well as primary brain tumor samples, we identified CD155 as the most highly expressed immune checkpoint. When murine DMG cells were cocultured with CD8+ T cells, silencing of CD155 led to a marked increase in T cell-mediated killing. Strikingly, CD155-deficient DMG cells failed to grow in immunocompetent mice, and depletion of CD8+ T cells allowed these tumors to grow. CD155 also exerted cell-autonomous effects on tumor cells: silencing of CD155 induced apoptosis of DMG cells and delayed tumor growth in immunodeficient mice. Transcriptomic analyses identified Forkhead box M1 (FoxM1) as a key target of CD155. Notably, FoxM1 silencing also led to reduced proliferation of DMG cells in vitro and in vivo. Finally, treatment of DMG-bearing mice with Thio, a FoxM1-targeting agent, delayed tumor growth and prolonged survival. Conclusions: These studies demonstrate that CD155 regulates immune evasion and tumor growth in DMG, and suggest that targeting CD155 could be a valuable two-pronged therapeutic strategy for this disease.
- 10 August 2026
- Published by Oxford University Press (OUP) in Neuro-Oncology
Open AccessCD155 regulates tumor growth and susceptibility to T cell-mediated killing in diffuse midline glioma
Background: Diffuse midline glioma (DMG) is a devastating pediatric brain tumor with an unmet need for novel therapies. Immune-checkpoint inhibitors have failed to prolong survival of DMG patients. Methods: In this study, we screened for immune-checkpoint molecules in DMG, evaluated immunological responses to checkpoint targeting by coculture assays and depletion of immune cells in vivo, studied the effects of CD155 silencing by whole-transcriptome analyses and performed in vivo treatments with Thiostrepton (Thio). Results: In human and murine DMG cells, as well as primary brain tumor samples, we identified CD155 as the most highly expressed immune checkpoint. When murine DMG cells were cocultured with CD8+ T cells, silencing of CD155 led to a marked increase in T cell-mediated killing. Strikingly, CD155-deficient DMG cells failed to grow in immunocompetent mice, and depletion of CD8+ T cells allowed these tumors to grow. CD155 also exerted cell-autonomous effects on tumor cells: silencing of CD155 induced apoptosis of DMG cells and delayed tumor growth in immunodeficient mice. Transcriptomic analyses identified Forkhead box M1 (FoxM1) as a key target of CD155. Notably, FoxM1 silencing also led to reduced proliferation of DMG cells in vitro and in vivo. Finally, treatment of DMG-bearing mice with Thio, a FoxM1-targeting agent, delayed tumor growth and prolonged survival. Conclusions: These studies demonstrate that CD155 regulates immune evasion and tumor growth in DMG, and suggest that targeting CD155 could be a valuable two-pronged therapeutic strategy for this disease.
- Open Access
- 24 November 2025
- Published by American Association for Cancer Research (AACR)
Supplementary Table 3 from N-myc–Mediated Translation Control Is a Therapeutic Vulnerability in Medulloblastoma
Translation efficiency in Rapalink-1 and Rapamycin treated samples
- 24 November 2025
- Published by American Association for Cancer Research (AACR)
Open AccessSupplementary Table 3 from N-myc–Mediated Translation Control Is a Therapeutic Vulnerability in Medulloblastoma
Translation efficiency in Rapalink-1 and Rapamycin treated samples
- Open Access
- 24 November 2025
- Published by American Association for Cancer Research (AACR)
Supplementary Table 1 from N-myc–Mediated Translation Control Is a Therapeutic Vulnerability in Medulloblastoma
RNA abundance of Rapalink-1 and Rapamycin treated samples
- 24 November 2025
- Published by American Association for Cancer Research (AACR)
Open AccessSupplementary Table 1 from N-myc–Mediated Translation Control Is a Therapeutic Vulnerability in Medulloblastoma
RNA abundance of Rapalink-1 and Rapamycin treated samples
- Open Access
- 24 November 2025
- Published by American Association for Cancer Research (AACR)
Supplementary Table 2 from N-myc–Mediated Translation Control Is a Therapeutic Vulnerability in Medulloblastoma
RPF abundance of Rapalink-1 and Rapamycin treated samples
- 24 November 2025
- Published by American Association for Cancer Research (AACR)
Open AccessSupplementary Table 2 from N-myc–Mediated Translation Control Is a Therapeutic Vulnerability in Medulloblastoma
RPF abundance of Rapalink-1 and Rapamycin treated samples
- Open Access
- 24 November 2025
- Published by American Association for Cancer Research (AACR)
Supplementary Data from N-myc–Mediated Translation Control Is a Therapeutic Vulnerability in Medulloblastoma
7 Supplementary Figures and Legends
- 24 November 2025
- Published by American Association for Cancer Research (AACR)
Open AccessSupplementary Data from N-myc–Mediated Translation Control Is a Therapeutic Vulnerability in Medulloblastoma
7 Supplementary Figures and Legends
- Open Access
- 24 November 2025
- Published by American Association for Cancer Research (AACR)
Data from N-myc–Mediated Translation Control Is a Therapeutic Vulnerability in Medulloblastoma
Deregulation of neuroblastoma-derived myc (N-myc) is a leading cause of malignant brain tumors in children. To target N-myc-driven medulloblastoma, most research has focused on identifying genomic alterations or on the analysis of the medulloblastoma transcriptome. Here, we have broadly characterized the translatome of medulloblastoma and shown that N-myc unexpectedly drives selective translation of transcripts that promote protein homeostasis. Cancer cells are constantly exposed to proteotoxic stress associated with alterations in protein production or folding. It remains poorly understood how cancers cope with proteotoxic stress to promote their growth. Here, our data revealed that N-myc regulates the expression of specific components (∼5%) of the protein folding machinery at the translational level through the major cap binding protein, eukaryotic initiation factor eIF4E. Reducing eIF4E levels in mouse models of medulloblastoma blocked tumorigenesis. Importantly, targeting Hsp70, a protein folding chaperone translationally regulated by N-myc, suppressed tumor growth in mouse and human medulloblastoma xenograft models. These findings reveal a previously hidden molecular program that promotes medulloblastoma formation and identify new therapies that may have impact in the clinic.Significance:Translatome analysis in medulloblastoma shows that N-myc drives selective translation of transcripts that promote protein homeostasis and that represent new therapeutic vulnerabilities.
- 24 November 2025
- Published by American Association for Cancer Research (AACR)
Open AccessData from N-myc–Mediated Translation Control Is a Therapeutic Vulnerability in Medulloblastoma
Deregulation of neuroblastoma-derived myc (N-myc) is a leading cause of malignant brain tumors in children. To target N-myc-driven medulloblastoma, most research has focused on identifying genomic alterations or on the analysis of the medulloblastoma transcriptome. Here, we have broadly characterized the translatome of medulloblastoma and shown that N-myc unexpectedly drives selective translation of transcripts that promote protein homeostasis. Cancer cells are constantly exposed to proteotoxic stress associated with alterations in protein production or folding. It remains poorly understood how cancers cope with proteotoxic stress to promote their growth. Here, our data revealed that N-myc regulates the expression of specific components (∼5%) of the protein folding machinery at the translational level through the major cap binding protein, eukaryotic initiation factor eIF4E. Reducing eIF4E levels in mouse models of medulloblastoma blocked tumorigenesis. Importantly, targeting Hsp70, a protein folding chaperone translationally regulated by N-myc, suppressed tumor growth in mouse and human medulloblastoma xenograft models. These findings reveal a previously hidden molecular program that promotes medulloblastoma formation and identify new therapies that may have impact in the clinic.Significance:Translatome analysis in medulloblastoma shows that N-myc drives selective translation of transcripts that promote protein homeostasis and that represent new therapeutic vulnerabilities.
- Open Access
- 9 November 2023
- Published by Springer Nature in Nature Genetics
- Vol. 55 (12) , 2189-2199
Circular extrachromosomal DNA promotes tumor heterogeneity in high-risk medulloblastoma
Circular extrachromosomal DNA (ecDNA) in patient tumors is an important driver of oncogenic gene expression, evolution of drug resistance and poor patient outcomes. Applying computational methods for the detection and reconstruction of ecDNA across a retrospective cohort of 481 medulloblastoma tumors from 465 patients, we identify circular ecDNA in 82 patients (18%). Patients with ecDNA-positive medulloblastoma were more than twice as likely to relapse and three times as likely to die within 5 years of diagnosis. A subset of tumors harbored multiple ecDNA lineages, each containing distinct amplified oncogenes. Multimodal sequencing, imaging and CRISPR inhibition experiments in medulloblastoma models reveal intratumoral heterogeneity of ecDNA copy number per cell and frequent putative ‘enhancer rewiring’ events on ecDNA. This study reveals the frequency and diversity of ecDNA in medulloblastoma, stratified into molecular subgroups, and suggests copy number heterogeneity and enhancer rewiring as oncogenic features of ecDNA.
- 9 November 2023
- Published by Springer Nature in Nature Genetics
- Vol. 55 (12) , 2189-2199
Open AccessCircular extrachromosomal DNA promotes tumor heterogeneity in high-risk medulloblastoma
Circular extrachromosomal DNA (ecDNA) in patient tumors is an important driver of oncogenic gene expression, evolution of drug resistance and poor patient outcomes. Applying computational methods for the detection and reconstruction of ecDNA across a retrospective cohort of 481 medulloblastoma tumors from 465 patients, we identify circular ecDNA in 82 patients (18%). Patients with ecDNA-positive medulloblastoma were more than twice as likely to relapse and three times as likely to die within 5 years of diagnosis. A subset of tumors harbored multiple ecDNA lineages, each containing distinct amplified oncogenes. Multimodal sequencing, imaging and CRISPR inhibition experiments in medulloblastoma models reveal intratumoral heterogeneity of ecDNA copy number per cell and frequent putative ‘enhancer rewiring’ events on ecDNA. This study reveals the frequency and diversity of ecDNA in medulloblastoma, stratified into molecular subgroups, and suggests copy number heterogeneity and enhancer rewiring as oncogenic features of ecDNA.
- Open Access
- 31 March 2023
- Published by American Association for Cancer Research (AACR)
Supplementary Data from N-myc–Mediated Translation Control Is a Therapeutic Vulnerability in Medulloblastoma
7 Supplementary Figures and Legends
- 31 March 2023
- Published by American Association for Cancer Research (AACR)
Open AccessSupplementary Data from N-myc–Mediated Translation Control Is a Therapeutic Vulnerability in Medulloblastoma
7 Supplementary Figures and Legends
- Open Access
- 31 March 2023
- Published by American Association for Cancer Research (AACR)
Supplementary Data from N-myc–Mediated Translation Control Is a Therapeutic Vulnerability in Medulloblastoma
7 Supplementary Figures and Legends
- 31 March 2023
- Published by American Association for Cancer Research (AACR)
Open AccessSupplementary Data from N-myc–Mediated Translation Control Is a Therapeutic Vulnerability in Medulloblastoma
7 Supplementary Figures and Legends
- Open Access
- 31 March 2023
- Published by American Association for Cancer Research (AACR)
Supplementary Table 2 from N-myc–Mediated Translation Control Is a Therapeutic Vulnerability in Medulloblastoma
RPF abundance of Rapalink-1 and Rapamycin treated samples
- 31 March 2023
- Published by American Association for Cancer Research (AACR)
Open AccessSupplementary Table 2 from N-myc–Mediated Translation Control Is a Therapeutic Vulnerability in Medulloblastoma
RPF abundance of Rapalink-1 and Rapamycin treated samples